CD274 and neoplasm: These insights are clinically relevant as immune checkpoint inhibitors, particularly the PD-1/PD-L1 blockade, have become the standard of care as a first-line or combined treatment for persistent, recurrent, or metastatic cervical cancer patients with a combined positive score equal or greater than 1 (and are showing positive results with high-risk locally advanced patients), highlighting the therapeutic potential of combined therapies reversing T cell exhaustion to improve anti-tumor immunity and patient outcomes [63,64].